Hum Mol Genet 2007, 16:2333–2340.PubMedCrossRef 46. Balding DJ: A tutorial on statistical methods for population association studies. Nat Rev
Genet 2006,7(10):781–791.PubMedCrossRef 47. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, López MA, De Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martínez-Frías ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G: Geographical and ethnic variation of the 677C > T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings Selleckchem Ganetespib from over 7000 newborns from 16 areas world wide. J Med Genet 2003, 40:619–625.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions All authors participated to the conception, design, interpretation, elaboration of the findings of the study, drafting and revising the final elaborate. In particular, Dr. VB designed the study, wrote the paper and with Dr. FPC and Dr. LM performed patients genotyping experiments. Dr. SP selected and enrolled the patients and performed FDG PET-CT studies. Dr. AS performed quantitative PET measurements and with Dr. GR and Dr. SN analysed data. Prof. CG, Prof. MCG and Prof. CM participated in the elaboration
of the findings of the study, drafting and revising the final elaborate. All authors read and approved the final content of the manuscript.”
“Background Ovarian cancer remains learn more leading cause of death among patients with different gynecological
neoplasms. Although majority of the patients see more respond to the primary treatment with debulking surgery followed by paclitaxel and platinum-based chemotherapy, many of them experience relapse of the disease within few years after first-line therapy. Platinum compounds introduction to the ovarian cancer treatment was a corner stone in the therapy of this malignancy. Paclitaxel addition to platinum improves the results of chemotherapy [1, 2]. Nevertheless about one quarter of the patients does not respond to the therapy and those who initially benefit Phospholipase D1 from the treatment incline to experience disease recurrence. There are no molecular agents known to predict the response to the chemotherapy in ovarian cancer as well as patients’ outcome. Revelation of such markers could result in a more effective patient selection to the certain regimens and development of tailored chemotherapy in ovarian cancer. Recently, microtubule associated protein (MAP) Tau has been identified as a potential marker of response to paclitaxel in breast cancer. Tau protein (50–64 kD), a product of gene located in chromosome 17 (17q21) shows the ability of combining to beta-tubulin.